

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-14 (Cancelled)

Claim 15 (Previously presented): A unit dosage form for the treatment of a subject having cancer, said unit dosage form comprising a sub-therapeutic dose level of a pharmacologically active agent effective against said cancer,

wherein said sub-therapeutic dose comprises in the range of about 1% up to about 20% of the conventionally administered amount of said pharmacologically active agent.

Claim 16 (Original): A unit dosage form according to claim 15, wherein the pharmacologically active agent in the unit dosage form is selected from the group consisting of chemotherapeutic drugs, taxanes, epitholones, agents which modify microtubule activity or assembly, small molecule drugs, biologics, peptides, antibodies, enzymes, antisense therapeutics, polynucleotides, synthetic polynucleotide constructs, antiinfectives, antirejection drugs, analgesics/antipyretics, anesthetics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines/antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, hormones, hypoglycemic agents, hypolipidemic agents, proteins, nucleic acids, agents useful for erythropoiesis stimulation, antiulcer/antireflux agents, antinauseants/antiemetics, oil-soluble vitamins, mitotane, visadine, halonitrosoureas, anthrocyclines, and ellipticine.

Claim 17 (Previously presented): A unit dosage form according to claim 15, wherein the pharmacologically active agent is administered by one or more routes of administration selected from the group consisting of topical, oral, intraarticular, intracisternal, intraocular, intraventricular, intrathecal, intravenous, intramuscular, intraperitoneal, intradermal/transdermal/subcutaneous, intratracheal/inhalational, rectal, vaginal, intracranial, intraurethral, intrahepatic, intraarterial, intratumoral, and mucosal.

Claims 18-19 (Cancelled)

Claim 20 (Previously presented): A unit dosage form according to claim 15, wherein the pharmacologically active agent in the unit dosage form is a chemotherapeutic drug.

Claim 21 (Previously presented): A unit dosage form according to claim 15, wherein the pharmacologically active agent is administered intravenously.

Claim 22 (Previously presented): A unit dosage form according to claim 20, wherein said chemotherapeutic drug is a taxane.

Claim 23 (Previously presented): A unit dosage form according to claim 22, wherein said taxane is paclitaxel.

Claim 24 (Previously presented): A unit dosage form according to claim 22, wherein said taxane is taxotere.

Claim 25 (Previously presented): A unit dosage form according to claim 15, wherein said sub-therapeutic dose comprises in the range of about 1% up to about 10% of the conventionally administered amount of said pharmacologically active agent.

Claims 26-47 (Cancelled)

Claim 48 (New): A unit dosage form according to claim 16, wherein the pharmacologically active agent is an agent which modifies microtubule activity of assembly.

Claim 49 (New): A unit dosage form according to claim 16, wherein the pharmacologically active agent is an antibiotic.

Claim 50 (New): A unit dosage form according to claim 16, wherein the pharmacologically active agent is an antineoplastic.

Claim 51 (New): A unit dosage form according to claim 50, wherein the antineoplastic is a taxane or its derivative.

Claim 52 (New): A unit dosage form according to claim 50, wherein the antineoplastic is a paclitaxel or its derivative.

Claim 53 (New): A unit dosage form according to claim 16, wherein the pharmacologically active agent is an immunosuppressive agent.

Claim 54 (New): A unit dosage form according to claim 17, wherein the pharmacologically active agent is administered orally.

Claim 55 (New): A unit dosage form according to claim 25, wherein the pharmacologically active agent in the unit dosage form is selected from the group consisting of chemotherapeutic drugs, taxanes, epitholones, agents which modify microtubule activity or assembly, small molecule drugs, biologics, peptides, antibodies, enzymes, antisense therapeutics, polynucleotides, synthetic polynucleotide constructs, anti-infectives, antirejection drugs, analgesics/antipyretics, anesthetics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines/antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, hormones, hypoglycemic agents, hypolipidemic agents, proteins,

nucleic acids, agents useful for erythropoiesis stimulation, antiulcer/antireflux agents, antinauseants/antiemetics, oil-soluble vitamins, mitotane, visadine, halonitrosoureas, anthrocyclines, and ellipticine.

Claim 56 (New): A unit dosage form according to claim 25, wherein the pharmacologically active agent is administered by one or more routes of administration selected from the group consisting of topical, oral, intraarticular, intracisternal, intraocular, intraventricular, intrathecal, intravenous, intramuscular, intraperitoneal, intradermal/transdermal/subcutaneous, intratracheal/inhalational, rectal, vaginal, intracranial, intraurethral, intrahepatic, intraarterial, intratumoral, and mucosal.

Claim 57 (New): A unit dosage form according to claim 55, wherein the pharmacologically active agent in the unit dosage form is a chemotherapeutic drug.

Claim 58 (New): A unit dosage form according to claim 25, wherein the pharmacologically active agent is administered intravenously.

Claim 59 (New): A unit dosage form according to claim 57, wherein said chemotherapeutic drug is a taxane.

Claim 60 (New): A unit dosage form according to claim 59, wherein said taxane is paclitaxel.

Claim 61 (New): A unit dosage form according to claim 59, wherein said taxane is taxotere.

Claim 62 (New): A unit dosage form according to claim 55, wherein the pharmacologically active agent is an agent which modifies microtubule activity of assembly.

Claim 63 (New): A unit dosage form according to claim 55, wherein the pharmacologically active agent is an antibiotic.

Claim 64 (New): A unit dosage form according to claim 55, wherein the pharmacologically active agent is an antineoplastic.

Claim 65 (New): A unit dosage form according to claim 64, wherein the antineoplastic is a taxane or its derivative.

Claim 66 (New): A unit dosage form according to claim 64, wherein the antineoplastic is a paclitaxel or its derivative.

Claim 67 (New): A unit dosage form according to claim 55, wherein the pharmacologically active agent is an immunosuppressive agent.

Claim 68 (New): A unit dosage form according to claim 56, wherein the pharmacologically active agent is administered orally.

Claim 69 (New): A unit dosage form according to claim 15, wherein the pharmacologically active agent is encapsulated in a colloidal dispersion system.

Claim 70 (New): A unit dosage form according to claim 69, wherein the colloidal dispersion system comprises nanocapsules or microspheres.

Claim 71 (New): A unit dosage form according to claim 69, wherein the colloidal dispersion system comprises liposomes or oil-in-water emulsions.

Claim 72 (New): A unit dosage form according to claim 25, wherein the pharmacologically active agent is encapsulated in a colloidal dispersion system.

Claim 73 (New): A unit dosage form according to claim 72, wherein the colloidal dispersion system comprises nanocapsules or microspheres.

Claim 74 (New): A unit dosage form according to claim 72, wherein the colloidal dispersion system comprises liposomes or oil-in-water emulsions.